Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.23 USD | -1.23% |
|
-1.75% | -19.67% |
06-27 | Dynavax Reports First Participant Dosed in Shingles Vaccine Trial | MT |
06-27 | Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.67% | 1.49B | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Transcript : Dynavax Technologies Corporation, Q3 2021 Earnings Call, Nov 04, 2021